Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amiram Sananes

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Bioconjugate Chemistry|April 21, 2022
Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP InhibitionHezi Hayun, Valeria Arkadash, Amiram Sananes, et al.
The Journal of Biological Chemistry|June 24, 2018
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineeringAmiram Sananes, Itay Cohen, Anat Shahar, et al.
Scientific Reports|August 10, 2021
A KLK4 proteinase substrate capture approach to antagonize PAR1Eitan Rabinovitch, Koishiro Mihara, Amiram Sananes, et al.
Molecular Oncology|August 23, 2023
Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancersAmiram Sananes, Itay Cohen, Irit Allon, et al.
Journal of Medicinal Chemistry|May 23, 2020
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate CancerLior Rosenfeld, Amiram Sananes, Yuval Zur, et al.
Cancers|August 27, 2021
Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal AdenocarcinomaJuliana B Candido, Oscar Maiques, Melanie Boxberg, et al.
Journal of Medicinal Chemistry|September 14, 2018
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular ActivityElena De Vita, Peter Schüler, Scott Lovell, et al.
Cancer Biology & Therapy|July 21, 2015
Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft modelEinav Mayzlish-Gati, Dana Laufer, Christopher F Grivas, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Bioconjugate Chemistry|April 21, 2022
Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP InhibitionHezi Hayun, Valeria Arkadash, Amiram Sananes, et al.
The Journal of Biological Chemistry|June 24, 2018
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineeringAmiram Sananes, Itay Cohen, Anat Shahar, et al.
Scientific Reports|August 10, 2021
A KLK4 proteinase substrate capture approach to antagonize PAR1Eitan Rabinovitch, Koishiro Mihara, Amiram Sananes, et al.
Molecular Oncology|August 23, 2023
Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancersAmiram Sananes, Itay Cohen, Irit Allon, et al.
Journal of Medicinal Chemistry|May 23, 2020
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate CancerLior Rosenfeld, Amiram Sananes, Yuval Zur, et al.
Cancers|August 27, 2021
Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal AdenocarcinomaJuliana B Candido, Oscar Maiques, Melanie Boxberg, et al.
Journal of Medicinal Chemistry|September 14, 2018
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular ActivityElena De Vita, Peter Schüler, Scott Lovell, et al.
Cancer Biology & Therapy|July 21, 2015
Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft modelEinav Mayzlish-Gati, Dana Laufer, Christopher F Grivas, et al.
Pageof 1